FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications By Ogkologos - August 19, 2026 223 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IRAKLIA, IZALCO and IsaSocut studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR New on NCI Websites for June 2018 June 25, 2018 The Doctor Will See You Now…On the Screen July 2, 2020 Men’s skin cancer rates increase by 50% over decade June 24, 2021 Researchers Turn On PTEN Tumor-Suppressor Protein in Cancer Cells June 14, 2019 Load more HOT NEWS Limited Efficacy of Nivolumab plus Ipilimumab in Adenoid Cystic Carcinomas, but... Can’t Sleep? Tips for Coping with Insomnia Strong Independent Association of TILs with OS for Patients with ERBB2-positive... Annual Multicancer Early Detection Test Not Associated with a Lower Incidence...
